

ABVD Therapy

INDICATIONS FOR USE:

		Regimen	Reimbursement
INDICATION	ICD10	Code	Status
Hodgkin's Lymphoma	C81	00290a	Hospital

TREATMENT:

The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their independent medical judgement, to consider each patients individual clinical circumstances.

Treatment is administered on day 1 and day 15 of a 28 day treatment cycle for a maximum of 6-8 cycles or until disease progression or unacceptable toxicity develops.

Consideration can be given to the omission of bleomycin from subsequent cycles in patients with a negative PET-CT after two cycles of ABVD.

Facilities to treat anaphylaxis MUST be present when the systemic anti cancer therapy (SACT) is administered.

Admin. Order	Day	Drug	Dose	Route	Diluent & Rate	Cycle
1	1, 15	^a DOXOrubicin	25mg/m ²	IV Bolus	Into the side arm of a	Every 28 days for a
					fast running 0.9% NaCl	maximum of 6-8 cycles
					infusion	
2	1, 15	^b vinBLAStine	6mg/m ²	IV infusion	50ml NaCL 0.9% over 10	Every 28 days for a
					min	maximum of 6-8 cycles
3	1, 15	^c Dacarbazine	375mg/m ²	IV infusion	^d 250ml 0.9% NaCl over	Every 28 days for a
					30min	maximum of 6-8 cycles
4	1, 15	^{e,f} Bleomycin	10,000	IV Bolus	Into the side arm of a	Every 28 days for a
			International		fast running 0.9% NaCl	maximum of 6-8 cycles
			units/m ²		infusion	

^aLifetime cumulative dose of DOXOrubicin is 450mg/m².

In establishing the maximal cumulative dose of an anthracycline, consideration should be given to the risk factors belowⁱ and to the age of the patient.

^bvinBLAStine is a neurotoxic chemotherapeutic agent. Refer to <u>NCCP Guidance on the Safe Use of Neurotoxic drugs</u> (including Vinca Alkaloids) in the treatment of cancer

^cDacarbazine is sensitive to light exposure. All reconstituted solutions should be suitably protected from light also during administration (light-resistant infusion set).

^dConsideration should be given to recommended concentration and stability of product. The volume of infusion should be adjusted appropriately.

^eBleomycin dosing should only be expressed in terms of international units.

^fLifetime cumulative dose of bleomycin is 400,000 international units.

(Bleomycin has been associated with severe and life threatening respiratory complications. The total cumulative dose of bleomycin should NOT exceed 400,000 international units. The risk of pulmonary toxicity increases beyond a cumulative dose of 300,000 international units. Check the cumulative dose prior to each treatment).

NCCP Regimen: ABVD Therapy	Published: 11/11/2016 Review: 09/09/2026	Version number: 5a	
Tumour Group: Lymphoma NCCP Regimen Code: 00290	IHS Contributor: Dr Cliona Grant ISMO Contributor: Prof Maccon Keane	Page 1 of 7	
The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibly of the prescribing clinician. and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens			





ELIGIBILITY:

- Indications as above
- ECOG 0-3. Patients with an ECOG 4 may be considered for treatment at the discretion of the treating clinician

EXCLUSIONS:

- Hypersensitivity to DOXOrubicin, bleomycin, vinBLAStine, dacarbazine or any of the excipients.
- Cardiac assessment should be considered prior to the administration of DOXOrubicin in highrisk patients.
- A cumulative life-long dose of 450mg/m² of DOXOrubicin should only be exceeded with extreme caution as there is as risk of irreversible congestive heart failure.
- Bleomycin is contraindicated in patients with acute pulmonary infection or chest X-rays suggesting diffuse fibrotic changes or greatly reduced lung function.

PRESCRIPTIVE AUTHORITY:

The treatment plan must be initiated by a Consultant Medical Oncologist or a Consultant Haematologist working in the area of haematological malignancies

TESTS:

Baseline tests:

- FBC, renal and liver profile, blood glucose.
- ECG
- MUGA or ECHO should be considered prior to the administration of DOXOrubicin in highrisk patients
- Pulmonary Function Tests (PFTs) prior to bleomycin
- Neurotoxicity assessment
- Virology screen Hepatitis B (HBsAg, HBcoreAb) & C, HIV. *See Adverse Effects/Regimen Specific Complications re Hepatitis B Reactivation

Regular tests:

- FBC, renal and liver before day 1 and day 15 of each cycle (day 15 may not be necessary, refer to local policy)
- Neurotoxicity assessment prior to each cycle
- Cardiac function if clinically indicated.
- PFTs if clinically indicated

Disease monitoring:

Disease monitoring should be in line with the patient's treatment plan and any other test/s as directed by the supervising Consultant.

DOSE MODIFICATIONS:

• Any dose modification should be discussed with a Consultant.

NCCP Regimen: ABVD Therapy	Published: 11/11/2016 Review: 09/09/2026	Version number: 5a	
Tumour Group: Lymphoma NCCP Regimen Code: 00290	IHS Contributor: Dr Cliona Grant ISMO Contributor: Prof Maccon Keane	Page 2 of 7	
The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibly of the prescribing clinician. and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens			







Haematological:

- Full dose intensity should be maintained irrespective of neutrophil count
- G-CSF should be avoided as this may precipitate bleomycin lung toxicity. Use only following agreement with the treating consultant.
- If platelet count < 75 x 10⁹/L treatment may need to be delayed by one week, discuss with consultant

Renal and Hepatic Impairment:

Table 1: Dose modification of ABVD in renal and hepatic impairment

Drug	Renal Impairment		Hepatic Impairment			
DOXOrubicin	Dose reduction may be considered		Bilirubin (micromol/L)		Dose	
	in severe renal impairment –		20-51		50%	
	clinical decision.		51-85			25%
			>85		Omit	
			If AST 2-3 x normal, give 75% of dose If AST > 3 ULN give 50% dose			
Bleomycin	CrCl (ml/min)	Dose	Clinical	decision		
	>50	100%				
	10-50	75%				
	<10	50%				
vinBLAStine	No dose reduction necessary.		Bilirubi	n (micromol/L	AST/ALT/units	Dose
			26-51	or	60-180	50%
			>51	and	normal	50%
			> 51	and	>180	omit
Dacarbazine	CrCl (ml/min) Dose		Can be	hepatotoxic. Con	sider dose reducti	on
	45-60	80%				
	30-45	75%]			
	<30	70%	1			

Management of adverse events:

Table 2: Dose Modification of ABVD for Adverse Events

Adverse reactions	Recommended dose modification
Grade >2 Peripheral neuropathy	Dose reduction of vinBLAStine may be required at the
(vinBLAStine only)	discretion of the prescribing consultant
Bleomycin-Induced Pulmonary Toxicity:	Bleomycin should be discontinued in patients
	demonstrating clinical or radiographic evidence of
	pulmonary injury or significant deterioration of
	pulmonary diffusion capacity.
	Do not reintroduce bleomycin to patients with any
	bleomycin-induced lung injury.

NCCP Regimen: ABVD Therapy	Published: 11/11/2016 Review: 09/09/2026	Version number: 5a	
Tumour Group: Lymphoma NCCP Regimen Code: 00290	IHS Contributor: Dr Cliona Grant ISMO Contributor: Prof Maccon Keane	Page 3 of 7	
The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibly of the prescribing clinician. and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens			





SUPPORTIVE CARE:

EMETOGENIC POTENTIAL:

 As outlined in NCCP Classification Document for Systemic Anti-Cancer Therapy (SACT) Induced Nausea and Vomiting linked <u>here</u>

DOXOrubicin: Moderate (Refer to local policy)

vinBLAStine: Minimal (Refer to local policy)

Dacarbazine: High (Refer to local policy)

Bleomycin: Minimal (Refer to local policy)

Consider increased risk of vinca alkaloid-induced adverse effects due to inhibition of CYP3A4 by aprepitant.

For information:

Within NCIS regimens, antiemetics have been standardised by Medical Oncologists and Haemato-oncologists and information is available in the following documents:

- NCCP Supportive Care Antiemetic Medicines for Inclusion in NCIS (Medical Oncology) link here
- NCCP Supportive Care Antiemetic Medicines for Inclusion in NCIS (Haemato-oncology) link here

PREMEDICATIONS: None usually required

OTHER SUPPORTIVE CARE:

- All patients should receive irradiated blood products refer to local policy for notification procedure
- Tumour lysis syndrome prophylaxis for first cycle (Refer to local policy)
- Anti-viral prophylaxis (Refer to local policy)
- Mouth care prophylaxis (Refer to local policy)
- Constipation (vinBLAStine-induced) prophylaxis (Refer to local policy)

ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS:

The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details.

- **Neutropenia**: Fever or other evidence of infection must be assessed promptly and treated appropriately.
- **Cardiac Toxicity:** DOXOrubicin is cardiotoxic and must be used with caution in patients with a history of cardiac dysfunction.
- Pulmonary Toxicity: Bleomycin lung toxicity may occur in up to 10-20% with increased risk in age >40 years, smoking, renal impairment and G-CSF use. Pulmonary toxicity of bleomycin is both doserelated and age-related. It may also occur when lower doses are administered, especially in elderly patients, patients with reduced kidney function, pre-existing lung disease, previous or concurrent radiotherapy to the chest and in patients who need administration of oxygen. It is significantly enhanced by thoracic radiation and by hyperoxia used during surgical anaesthesia.
 - All patients complaining of shortness of breath require a CXR and PFTs prior to further administration of bleomycin. Bleomycin should be discontinued if any signs or CXR evidence of pulmonary infiltration/fibrosis develop, or if the transfer factor is <50% of the predicted value. Patients with pulmonary infiltrates should be treated with steroids and broad spectrum

NCCP Regimen: ABVD Therapy	Published: 11/11/2016 Review: 09/09/2026	Version number: 5a	
Tumour Group: Lymphoma NCCP Regimen Code: 00290	IHS Contributor: Dr Cliona Grant ISMO Contributor: Prof Maccon Keane	Page 4 of 7	
The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibly of the prescribing clinician. and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer			

This information is valid only on the day of printing, for any updates please check <u>www.hse.ie/NCCPchemoregimens</u>



ŀE

antibiotics.

- Extravasation: DOXOrubicin and vinBLAStine cause pain and tissue necrosis if extravasated (Refer to local policy).
- **Hypersensitivity:** There is a high risk of a hypersensitivity reaction with bleomycin.
- Hepatitis B Reactivation: Patients should be tested for both HBsAg and HBcoreAb as per local policy. If either test is positive, such patients should be treated with anti-viral therapy (Refer to local infectious disease policy). These patients should be considered for assessment by hepatology.

DRUG INTERACTIONS:

- DOXOrubicin cardiotoxicity is enhanced by previous or concurrent use of other anthracyclines, or other potentially cardiotoxic drugs (e.g. 5-Fluorouracil, cyclophosphamide, PACLitaxel or trastuzumab) or with products affecting cardiac function (e.g. calcium antagonists).
- Concomitant use of phenytoin and dacarbazine should be avoided since there is a risk of exacerbation of convulsions resulting from the decrease of phenytoin digestive absorption
- Concomitant use of live-attenuated vaccines should be avoided
- Dacarbazine is metabolised by cytochrome P450 (CYP1A1, CYP1A2 and CYP2E1). This must be taken into account if other medicinal products are co-administered with dacarbazine that are metabolised by the same hepatic enzymes.
- Consider increased risk of vinca alkaloid-induced adverse effects due to inhibition of CYP3A4 by aprepitant.
- Current drug interaction databases should be consulted for more information.

REFERENCES:

- Evens AM, Cilley J et al. G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Br J Haem 2007; 137 (6):545-552
- 2. Gobbi PG, Levis A, Chisesi T, et al. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 2005; 23(36):9198-207. Epub 2005 Sep 19.
- 3. Canellos GP et al. Long term follow up of Hodgkins disease trial. NEJM 2002; 346 (18):1417-1418.
- 4. Canellos GP et al. Chemotherapy of Advanced Hodgkin's Disease with MOPP, ABVD, or MOPP Alternating with ABVD NEJM 1992; 327(21): 1478-1484
- 5. Lynch RC and Advani RH. Risk-adapted treatment of advanced hodgkin lymphoma with PET-CT. Am Soc Clin Oncol Educ Book. 2016; 35:e376-85. doi: 10.1200/EDBK_159036. PMID: 27249744.
- 6. Krens S D, Lassche, Jansman G F G A, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. Lancet Onco/2019; 20:e201-08. <u>https://doi.org/10.1016/S1470-2045(19)30145-7</u>
- 7. Dosage Adjustment for Cytotoxics in Renal Impairment January 2009; North London Cancer Network.
- 8. Dosage Adjustment for Cytotoxics in Hepatic Impairment January 2009; North London Cancer Network.

NCCP Regimen: ABVD Therapy	Published: 11/11/2016 Review: 09/09/2026	Version number: 5a	
Tumour Group: Lymphoma NCCP Regimen Code: 00290	IHS Contributor: Dr Cliona Grant ISMO Contributor: Prof Maccon Keane	Page 5 of 7	
The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibly of the prescribing clinician. and is which the USE's terms of use any other to the prescribing clinician.			

This information is valid only on the day of printing, for any updates please check <u>www.hse.ie/NCCPchemoregimens</u>





- 9. NCCP Classification Document for Systemic Anti-Cancer Therapy (SACT) Induced Nausea and Vomiting. V5 2023. Available at: <u>https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/nccp-classificationdocument-for-systemic-anti-cancer-therapy-sact-induced-nausea-and-vomiting.pdf</u>
- 10. DOXOrubicin Summary of Product Characteristics Accessed Feb 2023. Available at: https://www.hpra.ie/img/uploaded/swedocuments/LicenseSPC_PA0437-026-002 03032016152104.pdf
- 11. vinBLAStine Summary of Product Characteristics Accessed Feb 2023. Available at: <u>https://www.hpra.ie/img/uploaded/swedocuments/Licence_PA0822-208-001_25022022211320.pdf</u>
- 12. Dacarbazine Summary of Product Characteristics Accessed Feb 2023. Available at:https://www.hpra.ie/img/uploaded/swedocuments/LicenseSPC_PA0437-040-001_23062009231504.pdf
- 13. Bleomycin Summary of Product Characteristics Accessed Jan 2021. Available at: https://www.medicines.org.uk/emc/product/4263/smpc

Version	Date	Amendment	Approved By
1	12/10/2016		Dr Cliona Grant
Ţ	15/10/2010		Prof Maccon Keane
		Updated to NCCP template	
2	26/11/2018	Clarification of administration of	Prof Maccon Keane
		dacarbazine	
		Updated treatment section	
		regarding omission of bleomycin.	Dr Cliona Grant
3	09/09/2021	Updated emetogenic potential,	
		supportive care and hepatitis B	Prof Maccon Keane
		reactivation recommendations	
Λ	21/10/2021	Removed reference to bleomycin mg	Brof Maccon Koano
4	21/10/2021	dosing	
E	10/07/2022	Updated emetogenic potential	Prof Maccon Koano
C	10/07/2025	section and drug interaction section.	
Updated information in the	Updated information in the	NCCD	
ρ	03/07/2024	Emetogenic Potential section.	NUCF

Comments and feedback welcome at oncologydrugs@cancercontrol.ie.

ⁱCardiotoxicity is a risk associated with anthracycline therapy that may be manifested by early (acute) or late (delayed) effects.

Risk factors for developing anthracycline-induced cardiotoxicity include:

- high cumulative dose, previous therapy with other anthracyclines or anthracenediones
- prior or concomitant radiotherapy to the mediastinal/pericardial area
- pre-existing heart disease

NCCP Regimen: ABVD Therapy	Published: 11/11/2016 Review: 09/09/2026	Version number: 5a	
Tumour Group: Lymphoma NCCP Regimen Code: 00290	IHS Contributor: Dr Cliona Grant ISMO Contributor: Prof Maccon Keane	Page 6 of 7	

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibly of the prescribing clinician. and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens



• concomitant use of other potentially cardiotoxic drugs

In establishing the maximal cumulative dose of an anthracycline, consideration should be given to the risk factors above and to the age of the patient.

NCCP Regimen: ABVD Therapy	Published: 11/11/2016 Review: 09/09/2026	Version number: 5a
Tumour Group: Lymphoma NCCP Regimen Code: 00290	IHS Contributor: Dr Cliona Grant ISMO Contributor: Prof Maccon Keane	Page 7 of 7
The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibly of the prescribing clinician. and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens		